Medicare Part D Coverage and Tremfya: What to Know

What Is Tremfya?

Tremfya is the brand name for guselkumab, a biologic medication that blocks interleukin-23, or IL-23, a protein involved in inflammatory immune responses. By targeting this pathway, Tremfya can help reduce inflammation affecting the skin, joints, or digestive tract.

Current FDA-approved uses include moderate-to-severe plaque psoriasis and active psoriatic arthritis in adults and qualifying children age 6 or older who weigh at least 40 kilograms, or approximately 88 pounds. Tremfya is also approved for adults with moderately to severely active ulcerative colitis or Crohn’s disease.

How Tremfya Is Administered

For plaque psoriasis and psoriatic arthritis, Tremfya is generally given as a subcutaneous injection at the beginning of treatment, again four weeks later, and then every eight weeks. Patients may receive instruction on administering the medication at home.

Treatment for ulcerative colitis or Crohn’s disease may begin with intravenous infusions in a medical facility or with a subcutaneous induction regimen, depending on the prescribed option. Maintenance treatment is administered by subcutaneous injection. This distinction matters because the location and method of administration may determine whether Medicare Part B or Medicare Part D processes the claim.

Does Medicare Part D Cover Tremfya?

Medicare Part D may cover Tremfya, particularly when a patient obtains the medication from a specialty pharmacy and administers it at home. However, every stand-alone Part D plan and Medicare Advantage prescription drug plan has its own formulary, which is the plan’s list of covered medications.

A plan may list Tremfya as a covered specialty drug, cover it only for certain diagnoses, or require the prescriber to prove that specific clinical conditions have been met. Another plan may prefer a different biologic and require the patient to try that treatment first. Coverage therefore depends on the exact plan, diagnosis, dose, formulation, pharmacy, and medical historynot simply on whether someone has a red, white, and blue Medicare card.

Medicare drug plans are required to cover a broad selection of prescription medications, but they do not have to include every drug. Tremfya is not part of a Medicare “protected class” for which plans generally must cover nearly all available medications.

Why Tremfya May Appear on a Specialty Tier

Biologic medications are often placed on specialty tiers because of their high prices and special handling requirements. Instead of charging a predictable flat copayment, a Part D plan may require coinsurancea percentage of the plan-negotiated price.

A specialty-tier placement does not mean the medication is medically superior or that it arrives in a tiny velvet case. It is primarily a cost-sharing category. The amount a patient pays can differ substantially from one plan to another, even when both plans technically cover Tremfya.

Common Coverage Restrictions

Before approving Tremfya, a plan may apply one or more utilization-management rules:

• Prior authorization: The prescriber must submit clinical information showing that Tremfya is medically necessary.
• Step therapy: The patient may have to try one or more preferred treatments before the plan will cover Tremfya.
• Quantity limits: The plan may restrict the amount dispensed during a specific period.
• Diagnosis restrictions: Coverage may be available for one FDA-approved condition but not automatically approved for another.
• Specialty-pharmacy requirements: The prescription may have to be filled through a particular in-network pharmacy.

Step therapy is a form of prior authorization that generally requires a patient to try a lower-cost or preferred medication before moving to a more expensive drug. Plans may consider generics, biosimilars, conventional therapies, or other biologics when establishing these requirements.

Could Medicare Part B Cover Some Tremfya Treatment?

Medicare Part B generally covers certain medications that a healthcare professional administers in a physician’s office, hospital outpatient department, or qualifying infusion center. Medicare Part D generally covers outpatient prescriptions that patients obtain through a pharmacy and administer themselves.

As a result, an intravenous Tremfya induction dose for ulcerative colitis or Crohn’s disease may be processed under Part B when it is furnished in an eligible clinical setting. Later self-administered maintenance injections may be processed under Part D. The exact arrangement depends on the provider, site of care, plan rules, specialty pharmacy, and billing method.

This split can produce two different sets of paperwork and costs during one treatment course. Patients should ask the prescribing office to perform a benefits investigation for both the induction and maintenance phases rather than assuming one approval covers everything.

How Much Could Tremfya Cost With Medicare Part D?

There is no universal Medicare price for Tremfya. Out-of-pocket expenses depend on the plan’s deductible, formulary tier, coinsurance rate, negotiated price, network pharmacy, coverage restrictions, and whether the patient receives Extra Help.

The 2026 Part D Deductible

The standard Medicare Part D benefit permits plans to charge a deductible of up to $615 in 2026. Some plans have a lower deductible, no deductible, or a deductible that applies only to certain drug tiers. After the deductible is satisfied, the patient typically pays a copayment or coinsurance for covered prescriptions.

The 2026 Out-of-Pocket Cap

For 2026, annual out-of-pocket spending on covered Part D medications is capped at $2,100. Once a beneficiary reaches the applicable threshold, the person owes no additional copayments or coinsurance for covered Part D drugs for the remainder of that calendar year.

This cap can be particularly meaningful for people taking high-cost biologics. However, it applies only to qualifying out-of-pocket spending for medications covered under the Part D benefit. Monthly premiums, medications excluded by the plan, and amounts paid outside Medicare instead of using the plan may not count toward the limit.

The cap also resets at the beginning of each calendar year. In other words, January may arrive with fresh optimism, a new deductible, and yet another request for an insurance card that has not changed since last week.

The Medicare Prescription Payment Plan

Every Medicare drug plan offers the Medicare Prescription Payment Plan. This voluntary option allows beneficiaries to spread eligible out-of-pocket prescription costs across monthly bills instead of paying the entire amount at the pharmacy when the prescription is filled.

The program can make early-year Tremfya expenses easier to budget, but it does not reduce the medication’s total cost. It changes the timing of payments, not the amount owed. Patients must also continue paying their regular plan premium.

How to Check Tremfya Coverage Before the First Dose

1. Identify the Exact Prescription

Confirm the diagnosis, dose, injection device, treatment schedule, and whether the medication will be administered at home or in a healthcare facility. A formulary search for the wrong strength or formulation can produce misleading results.

2. Search the Plan’s Current Formulary

Use the plan’s online formulary or Medicare Plan Finder to search for both “Tremfya” and “guselkumab.” Review the tier, estimated annual cost, deductible information, restrictions, and specialty-pharmacy requirements. Medicare Plan Finder allows users to enter medications and pharmacies when comparing plan expenses.

3. Call the Plan

Online information is useful, but a phone call can uncover details hidden behind cheerful phrases such as “coverage criteria apply.” Ask whether prior authorization or step therapy is required, which specialty pharmacy must dispense the drug, whether the prescribed diagnosis is covered, and how much the patient is expected to pay.

Record the representative’s name, the date, the call-reference number, and the answers provided. Insurance conversations become much easier when “someone told me” is upgraded to “Representative Maria stated this under reference number 84729.”

4. Ask the Prescriber to Start Authorization Early

Prior authorization may require office notes, diagnosis codes, previous treatment records, laboratory results, and an explanation of why preferred alternatives are inappropriate. Starting this process before a scheduled dose reduces the risk of treatment delays.

5. Confirm the Pharmacy

Some plans cover specialty drugs only when they are dispensed by a designated in-network specialty pharmacy. Using an out-of-network pharmacy could increase costs or result in no coverage at all. Medicare advises beneficiaries to check pharmacy networks because preferred and standard pharmacies can have different cost-sharing arrangements.

What to Do if a Medicare Plan Denies Tremfya

A denial is frustrating, but it is not necessarily the final decision. The first step is to obtain a formal coverage determination explaining why the plan denied the medication. The prescriber can then submit missing documentation, request an exception, or appeal the decision.

An exception request may ask the plan to cover Tremfya even though it is not on the formulary, waive a step-therapy requirement, or remove another coverage restriction. The prescribing clinician generally must provide a medical statement explaining why covered alternatives would be ineffective, inappropriate, or unsafe.

Medicare Part D has five levels of appeal. The first formal appeal is generally a redetermination by the plan. If waiting for a standard decision could seriously threaten the patient’s health or ability to regain function, the patient or prescriber may request an expedited decision.

Free assistance is available through State Health Insurance Assistance Programs, commonly called SHIP. A SHIP counselor can help beneficiaries understand denials, compare plans, and navigate appeals without selling an insurance product.

Ways to Lower Tremfya Costs

Apply for Medicare Extra Help

Extra Help, also known as the Part D Low-Income Subsidy, helps eligible Medicare beneficiaries pay prescription premiums, deductibles, and copayments. People can apply through Social Security at any time, and some beneficiaries qualify automatically because they receive Medicaid, Supplemental Security Income, or assistance from a Medicare Savings Program.

Understand Manufacturer Savings Rules

The Tremfya commercial savings program is intended for eligible patients with commercial or private insurance. It generally cannot be used to pay costs submitted to Medicare, Medicaid, TRICARE, or another government-funded insurance program.

Johnson & Johnson also operates a separate patient assistance program. Some people with Medicare or other government coverage may qualify for medication at no cost if they meet the current financial and program requirements. Eligibility is not guaranteed, and terms can change, so patients should verify the latest rules directly with the assistance program.

Check Independent Charitable Foundations

Independent nonprofit foundations may sometimes provide grants for insurance premiums or medication cost sharing. Availability depends on the patient’s diagnosis, income, insurance status, and whether a relevant fund is open. Some funds close after available money has been awarded and reopen later, so checking more than once may be worthwhile.

For example, the HealthWell Foundation has listed Tremfya among medications included in an autoimmune Medicare assistance fund. Listing a drug does not guarantee that funding is currently available or that a particular applicant will qualify.

Compare Plans Every Year

Part D formularies, pharmacy networks, premiums, deductibles, tiers, and prior-authorization criteria can change annually. A plan that worked beautifully this year may turn into an expensive pumpkin next year.

Review the Annual Notice of Change and compare plans using the exact Tremfya prescription. The lowest-premium plan is not always the least expensive option once specialty-drug costs are included.

Important Medical Considerations

Insurance approval does not determine whether Tremfya is medically appropriate. Before treatment, patients should discuss infections, tuberculosis exposure, vaccination history, liver concerns, allergies, pregnancy, and other medications with their healthcare professional.

Tremfya can increase the risk of infections and may cause serious allergic reactions. Patients are generally evaluated for tuberculosis before treatment. Liver testing is recommended before and during treatment for ulcerative colitis or Crohn’s disease, while live vaccines should be avoided during treatment.

Urgent medical care may be necessary for symptoms of a severe allergic reaction, such as difficulty breathing, swelling of the face or throat, chest tightness, or widespread hives. Patients should contact their healthcare professional about signs of infection or possible liver problems.

Experiences With Medicare Part D and Tremfya

The following scenarios are illustrative composites based on common coverage situations. They do not describe specific individuals and should not be treated as medical or insurance advice.

Experience One: The Prior-Authorization Paper Chase

Imagine a Medicare beneficiary named Linda whose dermatologist recommends Tremfya for plaque psoriasis after several other treatments stop controlling her symptoms. Linda checks her plan’s formulary and is relieved to see Tremfya listed. Celebration seems appropriateperhaps even cake.

Then the specialty pharmacy explains that “listed” does not mean “ready to ship.” The plan requires prior authorization and documentation showing that Linda has tried two preferred therapies. Her dermatologist’s office submits the request, but the plan denies it because one treatment date is missing from the records.

Instead of abandoning the prescription, Linda asks for the denial notice, calls the office, and provides details about the earlier treatment. The dermatologist sends updated records and explains why returning to the previous medication would be inappropriate. The plan approves Tremfya several days later.

The lesson is not that every authorization will be approved. It is that small documentation problems can cause denials that look more final than they are. Requesting the written reason and involving the prescriber quickly can keep the process moving.

Experience Two: Part B Induction and Part D Maintenance

Now consider Robert, who is prescribed Tremfya for moderately to severely active Crohn’s disease. His gastroenterologist recommends intravenous induction at an infusion center, followed by maintenance injections at home.

Robert initially assumes his Part D plan will cover the entire treatment. The provider’s benefits specialist explains that the infusion-center doses may be processed through Medicare Part B, while the take-home injections will require approval from his Part D plan and delivery from a specialty pharmacy.

Robert therefore faces two separate benefit checks. The infusion center confirms Part B coverage and any applicable cost sharing. At the same time, the gastroenterology office begins Part D prior authorization for the maintenance prescription. By coordinating both processes before the first dose, Robert reduces the risk that the infusion phase will end before the home medication is ready.

This scenario demonstrates why the question “Does Medicare cover Tremfya?” can have two answers during the same treatment plan. The administration setting can be almost as important as the medication itself.

Experience Three: The Plan That Changed the Rules

Finally, picture Denise, who has used Tremfya successfully for psoriatic arthritis throughout the year. Her existing Part D plan covers it through an in-network specialty pharmacy. When the annual plan notice arrives, she is tempted to toss it into the pile of documents labeled “later,” where paperwork goes to begin a new life.

Instead, Denise reviews the formulary changes and discovers that Tremfya will move to a different tier next year and require step therapy. She enters her medication and pharmacy into Medicare Plan Finder and compares estimated annual costs across available plans. One alternative plan has a slightly higher monthly premium but more favorable Tremfya coverage and a pharmacy arrangement that works with her rheumatologist.

Denise confirms the details with the new plan before enrolling and asks her doctor what documentation may be needed in January. She cannot eliminate every possible administrative surprise, but she avoids selecting a plan based only on its premium.

The broader lesson is simple: people taking specialty medications should review Part D coverage every year. Loyalty is a charming quality in friendships and pets. It is not always a cost-saving strategy for prescription drug plans.

Final Takeaway

Medicare Part D may cover Tremfya, but beneficiaries should verify that the medication is on their plan’s formulary, understand any prior-authorization or step-therapy rules, and confirm the required specialty pharmacy. Patients receiving intravenous induction should also determine whether those doses will be billed through Medicare Part B while later home injections are covered through Part D.

The 2026 Part D out-of-pocket cap offers important protection for covered medications, while the Medicare Prescription Payment Plan can spread qualifying expenses across the year. Extra Help, independent foundation grants, and manufacturer patient assistance may provide additional support for eligible individuals.

The most practical strategy is to coordinate among the prescriber, insurance plan, treatment facility, and specialty pharmacy before the first dose is due. A little preparation cannot make insurance paperwork exciting, but it can make it considerably less dramatic.